Skip to main content
EditorialOpen accessIn the abstractAre we Able to Harness the Immunomodulatory Power of Cytokines for Novel Autoimmune Disease Treatments?Giuseppe Nocentini, Graziella Migliorati, Carlo RiccardiSince the end of the 1970s, interleukin 2 (IL-2) has been known as a key player in T cell expansion/activation (Watson et al., 1980). In the late 1980s, some groups used IL-2 to stimulate the immune systems of tumour patients (Jacobs et al., 1986). The idea seemed brilliant and several attempts were made, but the results were disappointing (Lim et … …American Journal of Pharmacology and Toxicology, Vol. 10, Issue 2 · 22 Oct 2015 · 7,625 accessesView PDFCite